(Q39139980)

9 September 2017

Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH. (English)

1 reference

9 September 2017

5

Mitsune Tanimoto

1 reference

9 September 2017

7

Tohru Murayama

1 reference

9 September 2017

Masahiro Kizaki

1

1 reference

9 September 2017

Shinichiro Okamoto

2

1 reference

9 September 2017

Tetsuzo Tauchi

3

1 reference

9 September 2017

Hideo Tanaka

4

1 reference

9 September 2017

Koiti Inokuchi

6

1 reference

9 September 2017

Yoshio Saburi

8

1 reference

9 September 2017

Masayuki Hino

9

1 reference

9 September 2017

Mitsuru Tsudo

10

1 reference

9 September 2017

Taizo Shimomura

11

1 reference

9 September 2017

Yasushi Isobe

12

1 reference

9 September 2017

TARGET Investigators

13

1 reference

9 September 2017

25 October 2008

1 reference

International Journal of Hematology

9 September 2017

1 reference

9 September 2017

88

1 reference

9 September 2017

4

1 reference

9 September 2017

409-417

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-008-0186-0

9 September 2017

0 references

cites work

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-008-0186-0

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

12 December 2020

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

12 December 2020

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

12 December 2020

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

12 December 2020

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

12 December 2020

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

1 reference

12 December 2020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

12 December 2020

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

10.1007/S12185-008-0186-0

Identifiers

DOI

1 reference

9 September 2017

1 reference